Modest Alcohol Consumption Will Not Protect Against Obesity, T2DM Risk
An investigation explored dose-dependent effects of alcohol consumption of type 2 diabetes mellitus and obesity risk.
Diagnosis & Disease Information
Obesity May Contribute to Development of Defecation Disorders
Researchers sought to characterize the clinical effect of obesity on defecation disorders, such as fecal incontinence or constipation.
Semaglutide 2.4 mg Cuts MACE Risk in Obese, Overweight Patients
Semaglutide is a GLP-1 receptor agonist.
Oral Semaglutide 50 mg Reduces Bodyweight in Adults Without Type 2 Diabetes
A phase 3 clinical trial examined the efficacy of semaglutide 50 mg for treating overweight and obesity in adults without type 2 diabetes.
Significant Weight Loss Observed With Tirzepatide in Two Phase 3 Studies
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Wegovy Labeling Updated With Additional Option for Maintenance Dosing
Wegovy is a glucagon-like peptide-1 receptor agonist.
National Lipid Association Meeting Updates: Lifestyle Interventions, Metabolic Syndrome, and Diabetes
Highlights from National Lipid Association Scientific Sessions 2023 include metabolic syndrome, diabetes, HEAT assessment tool, and lifestyle interventions.
Semaglutide and Phentermine/Topiramate Linked to Greatest Body Weight Reduction
Researchers examined the safety and efficacy of several weight loss drugs approved for the management of obesity.
Prostate Cancer Diagnoses Less Likely in Obese Men
Latest findings are from a study of 36,756 men with universal access to PSA screening.
Tirzepatide Demonstrates Efficacy for Reducing Weight in Overweight and Obesity
A meta-analysis examined the safety and efficacy of tirzepatide for weight loss in individuals with overweight or obesity.
- Loading...
Loading...
Loading... 
Loading...